Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0198 | 0.1347 | 0.1629 |
Echinococcus granulosus | geminin | 0.0198 | 0.1347 | 0.1347 |
Entamoeba histolytica | hypothetical protein | 0.0201 | 0.137 | 0.205 |
Trichomonas vaginalis | hypothetical protein | 0.0586 | 0.4684 | 1 |
Trypanosoma brucei | Vps23 core domain containing protein, putative | 0.0384 | 0.2951 | 1 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0119 | 0.0666 | 0.0666 |
Schistosoma mansoni | tsg101-related | 0.1001 | 0.8267 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0201 | 0.137 | 0.205 |
Entamoeba histolytica | hypothetical protein | 0.0201 | 0.137 | 0.205 |
Schistosoma mansoni | tsg101-related | 0.1001 | 0.8267 | 1 |
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.0139 | 0.0833 | 0.0833 |
Leishmania major | hypothetical protein, conserved | 0.0384 | 0.2951 | 0.5 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0139 | 0.0833 | 0.1007 |
Entamoeba histolytica | hypothetical protein | 0.0201 | 0.137 | 0.205 |
Echinococcus multilocularis | geminin | 0.0198 | 0.1347 | 0.1347 |
Trypanosoma cruzi | Vps23 core domain containing protein, putative | 0.0384 | 0.2951 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1202 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0198 | 0.1347 | 0.1629 |
Echinococcus multilocularis | tumor susceptibility gene 101 protein | 0.1202 | 1 | 1 |
Echinococcus granulosus | tumor susceptibility gene 101 protein | 0.1202 | 1 | 1 |
Schistosoma mansoni | tsg101-related | 0.0818 | 0.6686 | 0.8088 |
Entamoeba histolytica | tumor susceptibility gene 101 protein, putative | 0.0818 | 0.6686 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.